|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6416998B1
(en)
|
1992-09-02 |
2002-07-09 |
Baylor College Of Medicine |
Plasmid encoding a modified steroid hormone
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
EP0665852A1
(en)
|
1993-07-09 |
1995-08-09 |
Amgen Boulder Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
CA2214649C
(en)
|
1995-03-08 |
2007-06-12 |
Zeling Cai |
Antigen presenting system and methods for activation of t-cells
|
|
US5763270A
(en)
|
1995-06-07 |
1998-06-09 |
Genemedicine, Inc. |
Plasmid for delivery of nucleic acids to cells and methods of use
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
ES2278390T3
(es)
|
1996-05-23 |
2007-08-01 |
The Scripps Research Institute |
Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
CZ298364B6
(cs)
|
1998-02-05 |
2007-09-05 |
Smithkline Beecham Biologicals S. A. |
Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
|
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
|
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US6790662B1
(en)
|
1999-03-12 |
2004-09-14 |
Ortho-Mcneil Pharmaceutical, Inc. |
Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
|
|
PT1187629E
(pt)
|
1999-04-19 |
2005-02-28 |
Glaxosmithkline Biolog Sa |
Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
US20040071671A1
(en)
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20030211603A1
(en)
|
2001-08-14 |
2003-11-13 |
Earp David J. |
Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003263653A1
(en)
|
2002-09-27 |
2004-04-19 |
Daewoong Co., Ltd. |
A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
US7682828B2
(en)
|
2003-11-26 |
2010-03-23 |
Whitehead Institute For Biomedical Research |
Methods for reprogramming somatic cells
|
|
AU2005282414C1
(en)
|
2004-09-08 |
2011-04-07 |
Wisconsin Alumni Research Foundation |
Culturing human embryonic stem cells
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
EP3147296A1
(en)
|
2005-11-14 |
2017-03-29 |
Merial, Inc. |
Gene therapy for renal failure
|
|
US8129187B2
(en)
|
2005-12-13 |
2012-03-06 |
Kyoto University |
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
|
|
US8278104B2
(en)
|
2005-12-13 |
2012-10-02 |
Kyoto University |
Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
|
|
CA2643337C
(en)
|
2006-03-01 |
2016-01-12 |
Janssen Pharmaceutica N.V. |
Cancer treatment combining lymphodepleting agent with ctls and cytokines
|
|
US9598673B2
(en)
*
|
2006-05-19 |
2017-03-21 |
Creative Medical Health |
Treatment of disc degenerative disease
|
|
JP5543207B2
(ja)
|
2006-10-04 |
2014-07-09 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
|
|
JP5813321B2
(ja)
|
2007-03-23 |
2015-11-17 |
ウィスコンシン アラムニ リサーチ ファンデーション |
体細胞の再プログラム化
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
US9683232B2
(en)
|
2007-12-10 |
2017-06-20 |
Kyoto University |
Efficient method for nuclear reprogramming
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
EP3279314A1
(en)
|
2008-06-04 |
2018-02-07 |
Cellular Dynamics International, Inc. |
Methods for the production of ips cells using non-viral approach
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
CA2734128A1
(en)
|
2008-08-12 |
2010-02-18 |
Cellular Dynamics International, Inc. |
Methods for the production of ips cells
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
DK2356221T3
(en)
|
2008-10-24 |
2019-02-18 |
Wisconsin Alumni Res Found |
Pluripotent stem cells obtained by non-viral reprogramming
|
|
WO2010141801A2
(en)
|
2009-06-05 |
2010-12-09 |
Cellular Dynamics International, Inc. |
Reprogramming t cells and hematophietic cells
|
|
CA2770412C
(en)
|
2009-08-07 |
2018-09-11 |
Kyoto University |
Method of efficiently establishing induced pluripotent stem cells
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
WO2011056971A2
(en)
|
2009-11-04 |
2011-05-12 |
Cellular Dynamics International, Inc. |
Episomal reprogramming with chemicals
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
US9005967B2
(en)
|
2010-01-22 |
2015-04-14 |
Kyoto University |
Myc variants improve induced pluripotent stem cell generation efficiency
|
|
HUE030100T2
(en)
|
2010-02-19 |
2017-04-28 |
Xencor Inc |
New CTLA4-IG immunoadhesins
|
|
WO2011159684A2
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
Generation of induced pluripotent stem cells from small volumes of peripheral blood
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
CN104080797A
(zh)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
EP2844743B1
(en)
|
2012-05-03 |
2021-01-13 |
Fred Hutchinson Cancer Research Center |
Enhanced affinity t cell receptors and methods for making the same
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
MX370148B
(es)
|
2012-10-02 |
2019-12-03 |
Memorial Sloan Kettering Cancer Center |
Composiciones y su uso para inmunoterapia.
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
EP3755347B1
(en)
*
|
2018-02-21 |
2025-06-25 |
Board of Regents, The University of Texas System |
Universal antigen presenting cells and uses thereof
|